Detailed Narrative
2024 Performance Highlights
Ventas exceeded its full-year normalized FFO per share guidance, reaching $3.19, driven by robust senior housing organic growth and accretive investments. The company achieved nearly 16% SHOP same-store cash NOI growth and a 300 basis point increase in same-store occupancy. This performance contributed to a significant increase in scale, with annualized EBITDA reaching $2.2 billion, and improved leverage, bringing net debt-to-EBITDA to 6.0x, within the long-term target range.
Senior Housing Growth Strategy
Ventas is capitalizing on an unprecedented🌐 multi-year growth opportunity in senior housing, fueled by a projected 28% surge in the 80+ population over the next five years and historically low new construction starts. The company's Ventas OI platform, proprietary data analytics, and strong operator relationships enable it to capture market share and drive organic growth. Management emphasized being in the 'early innings' of this cycle, with compelling supply-demand dynamics expected to persist.
Strategic Investments & Capital Recycling
In 2024, Ventas closed $1.9 billion in senior housing investments, including $1.4 billion in Q4, targeting high-performing assets with 90% average occupancy in markets with strong net absorption. These investments were funded with equity and met criteria for 7-8% year one NOI yield and low- to mid-teens unlevered IRRs. For 2025, the company has line of sight on $1 billion in senior housing investments, principally equity-funded, and plans to raise $200 million through capital recycling, primarily from skilled nursing dispositions.
Portfolio Repositioning and SHOP Expansion
Ventas plans a significant portfolio repositioning by converting 45 large-scale senior housing communities, comprising about 5,700 units, from triple-net to SHOP. These communities, currently 77% occupied, will transition to five proven operators, with the goal of doubling their NOI. This conversion is expected to increase the SHOP footprint by 8% in units and elevate SHOP's contribution to over 50% of enterprise NOI by year-end 2025, although the FFO impact is largely a 2026 story.
Balance Sheet and Capital Allocation
The company strengthened its balance sheet, achieving a net debt-to-EBITDA of 6.0x, a 90-basis-point improvement year-over-year, now within its long-term target range of 5-6x. Robust liquidity of nearly $4 billion at year-end 2024, including $250 million of unsettled forward equity, supports future investments. Ventas also increased its quarterly dividend by 7%, reinforcing its commitment to shareholder returns.
Medical Office & Research Performance
The outpatient medical and research business delivered continued compounding growth of 3% in 2024, with research growing 4.6% and outpatient medical 2.6%. The Santerre portfolio, a key part of the medical office segment, showed strong improvements, including a material increase in tenant satisfaction from the lowest to the third quartile, 82% TTM retention, a 210 bps occupancy increase, and 4% NOI growth.